Indirubin, a bis-indole obtained from various natural sources, is responsible for the reported antileukemia activity of a Chinese Medicinal recipe, Danggui Longhui Wan. However, its molecular mechanism of action is still not well understood. In addition to inhibition of cyclindependent kinases and glycogen synthase kinase-3, indirubins have been reported to activate the aryl hydrocarbon receptor (AhR), a cotranscriptional factor. Here, we confirm the interaction of AhR and indirubin using a series of indirubin derivatives and show that their binding modes to AhR and to protein kinases are unrelated. As reported for other AhR ligands, binding of indirubins to AhR leads to its nuclear translocation. Furthermore, the apparent survival of AhRÀ/À and þ / þ cells, as measured by the MTT assay, is equally sensitive to the kinase-inhibiting indirubins. Thus, the cytotoxic effects of indirubins are AhR-independent and more likely to be linked to protein kinase inhibition. In contrast, a dramatic cytostatic effect, as measured by actual cell counts and associated with a sharp G1 phase arrest, is induced by 1-methyl-indirubins, a subfamily of AhR-active but kinase-inactive indirubins. As shown for TCDD (dioxin) , this effect appears to be mediated through the AhR-dependent expression of p27 KIP1 . Altogether these results suggest that AhR activation, rather than kinase inhibition, is responsible for the cytostatic effects of some indirubins. In contrast, kinase inhibition, rather than AhR activation, represents the main mechanism underlying the cytotoxic properties of this class of promising antitumor molecules.
Introduction
The bis-indole indirubin has been identified as the main active ingredient of a traditional Chinese medicinal recipe, Danggui Longhui Wan, used to treat various diseases including chronic myelocytic leukemia (reviews in Tang and Eisenbrand, 1992; Xiao et al., 2002) . Indirubin can be obtained from four different natural sources: (1) a variety of indigo-producing plants (Balfour-Paul, 1998; Maugard et al., 2001) , (2) a number of mollusks, essentially belonging to the Muricidae family (reviewed in Cooksey, 2001) , (3) urine of healthy and diseased patients (Dealler et al., 1988; Adachi et al., 2001 and references therein), and (4) various natural or recombinant bacteria (reviewed in Chotani et al., 2000; Gillam et al., 2000; MacNeil et al., 2001) . Indirubin is a dark red isomer of the blue indigo. Both derive from the spontaneous, nonenzymatic dimerization of isatin and indoxyl, two colorless precursors found either free or conjugated to carbohydrates. Interest in this family of compounds increased when indirubin and analogues (collectively referred to as indirubins) were found to inhibit the cell cycle regulating cyclin-dependent kinases (CDKs) (Hoessel et al., 1999) , and glycogen synthase kinase -3 (GSK-3) (Leclerc et al., 2001) . Evidence suggests that the antiproliferative effects of indirubins derive from their ability to inhibit CDKs (Damiens et al., 2001; Marko et al., 2001) . However, the exact mechanisms underlying the antimitotic and antitumor properties of indirubins remain to be identified.
Indirubin and indigo have recently been discovered as potent ligands of the aryl hydrocarbon receptor (AhR), also known as the dioxin receptor (Adachi et al., 2001; Kawanishi et al., 2003) . AhR, a member of the bHLH/ PAS family of transcriptional regulators, mediates the effects of many xenobiotics such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and indole-containing compounds (reviewed in Hankinson, 1995; Denison and Nagy, 2003) . However, despite the large number of compounds found to interact with AhR, its natural ligands remain to be identified (Denison and Nagy, 2003) . The binding of AhR to a ligand leads to its translocation from the cytoplasm to the nucleus, followed by complex formation with the aryl hydrocarbon receptor nuclear translocator (ARNT). This complex then binds to xenobiotic-responsive element (XRE) and stimulates the transcription of a wide variety of genes, including cytochrome P450 Cyp1A1, p27 kip1 , myristoyltransferase, etc. (Rowlands and Gustafsson, 1997; Denison et al., 1998; Kolluri et al., 1999 Kolluri et al., , 2001 Santini et al., 2001) . Several arguments support a link between AhR activation and cell cycle control (Ge and Elferink, 1998; Elferink et al., 2001; reviewed in Elferink, 2003) . The recent discovery of the interaction of indirubin with AhR opened the possibility that indirubins prevent cell proliferation via an action through AhR. This could raise some concern about the potential use of these compounds since AhR activation has been directly linked to carcinogenesis (Hankinson, 1995; Shimizu et al., 2000; Safe, 2001; Andersson et al., 2002) . In contrast, some AhR agonists have also been reported to cause growth inhibition of various tumor cell lines and as such could be evaluated for their use in antitumor therapy (Bradshaw et al., 2002; Koliopanos et al., 2002; Safe and McDougal, 2002) .
In this article, we report the results of experiments designed to investigate the contribution of indirubin/ AhR interaction to the antiproliferative properties of indirubins. We first confirm the interaction between AhR and a series of indirubin analogues using two distinct AhR reporter systems. We show that the survival of AhR À/À and þ / þ cells, as measured by the MTT assay, is equally sensitive to the kinaseinhibiting indirubins and thus largely AhR-independent, therefore more likely linked to protein kinase inhibition. In contrast, the kinase-inactive, but AhR-active, 1-methyl-indirubins, show a striking AhR-dependent cytostatic effect leading to an arrest of cells in G1. This effect appears to be directly linked to the AhRdependent expression of p27 KIP1 , as it is not observed in AhR À/À cells. Altogether these results suggest that kinase inhibition, rather than AhR activation, represents the main mechanism underlying the cytotoxic properties of this class of promising antitumor molecules. In contrast, AhR activation, rather than kinase inhibition, is responsible for the cytostatic effects induced by some indirubins.
Results

Indirubins interact with AhR, yet less potently than TCDD
Human AhR and ARNT have been coexpressed stably in yeast and the interaction was coupled to a bgalactosidase reporter system allowing the detection of AhR agonists (Miller, 1997) . Using this reporter assay to screen for natural AhR agonists in human urine, Adachi et al. (2001) reported that both indirubin and indigo were potent activators of AhR-dependent transcription. Using the same yeast reporter assay, we tested a series of indirubin analogues for their ability to activate AhR-dependent transcription (Table 1) . Additionally, we also tested these compounds in a newly described AhR agonist detection bioassay. In this assay, ligand and AhR-dependent transcription is measured by the amount of enhanced green fluorescent protein (EGFP) expression which is stably transfected into a mouse hepatoma cell line (Nagy et al., 2002a, b) (Table 1, Figure 1 ). TCDD was used as a positive control. Our results confirmed that indirubins, including indirubin-3 0 -oxime (IO), the analogue commonly used in cell cycle studies (Damiens et al., 2001; Marko et al., 2001) , are potent AhR agonists, although much less than TCDD in the mammalian reporter assay (Table 1, Figure 1 ).
We also tested the effect of indirubin analogues on two protein kinases, CDK1/cyclin B and GSK-3 (Table 1) . Interestingly, the indirubin structure/activity relationships with respect to AhR binding and kinase inhibition were only distantly comparable (Table 1) (see  Discussion) .
As revealed by cocrystal structures (Hoessel et al., 1999; Davies et al., 2001; Meijer et al., 2003) the indirubin N1 acts as a H-bond donor in the indirubin/ kinase binding. Consequently, methylation at this site should clearly eliminate an essential bonding and inactivate indirubins as kinase inhibitors (Meijer et al., 2003; Polychronopoulos et al., 2004) . Based on this observation, we envisaged the synthesis of 1-methyl-indirubin, 1-methyl-indirubin-3 0 -oxime (MeIO), 1-methyl-6-bromo-indirubin and 1-methyl-6-bromo-indirubin-3 0 -oxime (MeBIO). Indeed, these compounds were found to be the most striking examples of selectivity, as they were very potent in the AhR assays while being essentially inactive on CDKs and GSK-3, compared to their nonmethylated counterparts, indirubin (IO) and 6-bromo-indirubin-3 0 -oxime (BIO), respectively.
These results show that indirubins are potent AhR ligands in both reporter systems, and that their binding modes to AhR and to protein kinases are unrelated.
Indirubins trigger cytoplasm to nucleus translocation of AhR
To confirm the interaction of indirubins with AhR in living cells, we investigated their effect on AhR intracellular distribution ( Figure 2 ). The nuclear translocation of AhR after treatment with a ligand is a wellknown consequence of AhR/ligand interaction (Elbi et al., 2002) . Wild-type Hepa-1 and ARNT-mutant cells were treated for 90 min with various indirubins, TCDD or DMSO as a control. The cells were then fixed and examined by indirect immunofluorescence microscopy following staining with an anti-AhR antibody ( Figure 2 ). As expected, in the absence of ligand, AhR showed both cytoplasmic and nuclear distribution in wild-type Hepa-1 (Figure 2a -c) and in ARNT-mutant cells (Figure 2g, j) .
Indirubins, kinases and aryl hydrocarbon receptor M Knockaert et al Upon addition of IO, AhR rapidly localized to the nucleus (Figure 2d-f) . MeBIO treatment also caused redistribution of AhR to the nucleus, and the nuclear translocation was independent of the presence of functional ARNT (Figure 2i, l) . This finding was similar to the nuclear translocation kinetics of AhR observed in TCDD-treated wild-type Hepa-1 cells and ARNT mutant cells (Figure 2h, k) . All other indirubins tested, such as BIO, 0 -oxime, also triggered ARNT-independent nuclear redistribution of AhR (data not shown). These results demonstrate that indirubins are potent and functional ligands for AhR in living cells and that ARNT is not necessary for indirubin-induced nuclear translocation of AhR.
Cell cycle inhibitory properties of indirubins are AhRdependent, but kinase inhibition-independent
To investigate the relative contributions of AhR signaling and kinase inhibition to the cellular effects of indirubins, we used IO, MeIO, BIO and MeBIO and two mouse hepatoma cell lines, 5L (AhR þ / þ ) and the AhR-deficient subclone, BP8 (AhR À/À) (Weiss et al, 1996; Kolluri et al.,. 1999) . We first confirmed the AhR status in these two cell lines by Western blotting using anti-AhR antibody (Figure 3) . In contrast to BP8 cells, AhR expression was detected in 5L cells.
We next investigated the effects of IO and MeIO (20 mM) on the proliferation rate of 5L and BP8 cell lines, by counting directly the number of live cells after 24 and 48 h of exposure to the indirubins (Figure 4 ). This approach clearly showed that IO blocks the proliferation of both cell types, independent of AhR expression. In contrast, MeIO, a potent AhR ligand, but kinase-inactive indirubin, reduced the rate of proliferation only in 5L cells (Figure 4a) , and did not effect the proliferation of AhR À/À cell line BP8 that was, in fact, slightly stimulated (Figure 4b ). This result indicates that MeIO has an AhR-dependent and kinase-independent antiproliferative effect in mouse hepatoma cells. TCDD also triggered an AhR-dependent arrest in G1 (Figure 5b ), as previously reported (Elferink, 2003) . Altogether these results show that AhR-active indirubins arrest cells in G1 in an AhR-dependent, but kinase-independent manner.
Cytotoxic properties of indirubins are AhR-independent, but kinase inhibition-dependent
To investigate the effects of indirubins on cell survival, 5L and BP8 cells were exposed to a range of concentrations of each indirubin for 24 and 48 h and the global survival rate was estimated using the MTT assay, an assay of cell viability based on a mitochondrial enzyme assay ( Figure 6 ). Results are expressed as a percentage of control, untreated cells. Two main conclusions stem from these experiments. First, the survival of both AhR À/À and AhR þ / þ cells was equally sensitive to IO and BIO, as shown by dose-response curves obtained after 24 and 48 h (data not shown) exposure to the drugs (Figure 6a, b) . Second, the survival of both cell types was apparently not affected by MeIO and MeBIO, the kinase inactive, yet AhR-active, indirubins (Figure 6b, d) . The possibility remains that MeIO and MeBIO block cell cycle without affecting the mitosis-associated increase in mitochondria number, on which the MTT assay is essentially based. These results indicate that IO and BIO have a kinasedependent but AhR-independent cytotoxic effect in mouse hepatoma cells.
Indirubins stimulate p27
KIP1 expression in an AhRdependent manner Activation of AhR leads to the enhanced expression of a variety of genes (review in Elferink, 2003) , including the cytochrome P450 CYP1A1 (Santini et al., 2001 ) and the CDK inhibitor p27 KIP1 (Kolluri et al., 1999) . We first confirmed by Western blotting that TCDD upregulates the expression of both CYP1A1 and p27 KIP1 in the 5L but not in the BP8 cells (Figure 7 ; data not shown). Furthermore dose-dependent upregulation of p27 KIP1 was also found in 5L cells, but not BP8 cells, exposed to the AhR-active MeIO (Figure 7a ). After testing various indirubins, and comparing them to TCDD, we found that the level of p27 KIP1 induction correlated significantly with the potency of each indirubin to interact with AhR rather than its ability to inhibit cyclin-dependent kinases (Figure 7b ). Both MeIO and MeBIO were very effective p27 KIP1 inducers, while IO and BIO induced a modest, but detectable increase in p27 KIP1 level. These results show that indirubins activate p27 KIP1 expression in an AhR-dependent, but kinaseindependent manner. 
Discussion
Indirubins are functional AhR ligands
Using a yeast reporter assay for AhR signaling, Adachi et al. (2001) reported the identification of indirubin as a potent AhR ligand, confirming an earlier observation by Rannug et al. (1992) . In this study, we present several lines of evidence, which clearly support and extend previous findings: (1) determination of the binding characteristics of indirubin analogues to AhR by use of a mammalian reporter system based on AhRdependent stable expression of EGFP in mouse hepatoma cell line; (2) visualization of the effect of indirubins on the intracellular localization of AhR; (3) the effects of indirubins on p27 KIP1 expression and G1 arrest in AhR þ / þ , but not in AhR À/À cells. Our results demonstrate that indirubins clearly act as functional AhR ligands in mammalian cells. Using the yeast reporter assay, we found that some indirubins are more potent AhR activators than TCDD (Table 1) . However, the yeast reporter assay was clearly less sensitive to TCDD than the mammalian reporter assay. In the mammalian reporter assay, indirubins appear to be much less potent AhR activators than TCDD. In fact, only a limited correlation was observed between the EC 50 values obtained using the two reporter systems with 24 indirubins (Table 1) . There are several reasons that could explain why the AhR reporter assays are only partially quantitative and poorly comparable: (1) other indirubin-interacting proteins, such as kinases, are competing with AhR for indirubin binding; (2) Figure 2 Indirubins induce nuclear translocation of AhR. Upper panel: Wild-type Hepa-1 cells were treated for 90 min with either DMSO as a control (a-c) or 25 mM IO (d-f). The cells were fixed and AhR distribution was detected by indirect immunofluorescence microscopy using anti-AhR antibody (a, c and d, f). Total DNA was stained with DAPI (b, c and e, f). Lower panel: Wild-type Hepa-1 (g-i) and ARNT mutant (j-l) cells were treated for 90 min with either DMSO as a control (g, j) or 10 nM TCDD (h, k) or 25 mM MeBIO (i, l). Intracellular distribution of AhR was analysed as described above. Scale bar, 10 mm conversely, unidentified endogenous AhR ligands may be competing to a variable extent with indirubins in the reporter systems; (3) the solubility of and the permeability of cells to these hydrophobic compounds and their intracellular distribution is not known, but these factors are very likely to influence the fraction of indirubins which interacts with AhR and is thus detected in the assays; (4) the response of these reporter systems is complex as the intensity of maximal AhR activation varies from compound to compound, some indirubins even being inhibitory at higher concentrations (data not shown), and furthermore, as some ligands may induce their own degradation through AhR-dependent induction of cytochrome P450 (Spink et al., 2003) .
Structure/activity relationship analysis carried out with a large number of synthetic ligands suggests that the AhR ligand-binding pocket can accommodate planar ligands with maximal dimensions of 14 Å Â 12 Å Â 5 Å (for a review, see Denison and Nagy, 2003) . AhR-interacting indirubins, such as MeBIO (12.6 Å Â 7.9 Å Â 1.8 Å ), clearly meet these requirements. In the absence of an available AhR/ligand cocrystal structure, we can only speculate on the atomic basis of AhR/indirubin interactions. Ligand binding has been mapped to the second PAS domain of the AhR protein (Fukunaga et al., 1995) . A model for recognition of TCDD by AhR, based on the crystal structure of the conserved PAS domain of the heme-binding domain of the bacterial O 2 sensing FixL protein, has been proposed (Procopio et al., 2002) . Another 3D model of AhR has been published recently (Jacobs et al., 2003) . According to these models, AhR should be able to accommodate the flat hydrophobic indirubins in a way similar to TCDD. According to these models also, indirubins meet the requirements for AhR binding, that is, a nucleophilic site in the central part of the ligand and electrophilic sites at the sides of the principal molecular axis.
Interestingly, there is little correlation between the potency of indirubins as AhR activators and kinase inhibitors. Although methylation at N1 provides kinaseinactive indirubins but potent AhR agonists, we were unable to find kinase-inhibiting indirubins that were inactive on AhR. Most ATP-competing kinase inhibitors are planar, hydrophobic, small molecular weight compounds, like AhR ligands. This raises the intriguing possibility that, besides indirubins, AhR may actually bind other kinase inhibitors. This is supported by the very recent observation showing that the Jun N-terminal kinase inhibitor SP600125 is a ligand of AhR (Joiakim et al., 2003) .
Indirubins as mimetics of natural AhR ligands
AhR was discovered as the receptor for dioxin, benzo[a]pyrene and other related, man-made pollutants. However, several arguments suggest that AhR is the receptor for endogenous ligands (reviewed in Denison and Nagy, 2003) : (1) a phylogenetic survey indicates that the AhR arose over 450 million years ago, that is, in a variety of organisms evolving in different chemical environments, long before environmental pollution by anthropogenic compounds started (Hahn, 2002) ; (2) AhR is expressed in various tissues and at different developmental time points, which is inconsistent with a unique role in defence against environmental chemicals (Jain et al., 1998; Kuchenhoff et al., 1999) ; (3) the loss of function studies that were carried out in mice by different laboratories suggest that AhR plays a role in development, in the absence of exogenous ligand Indirubins, kinases and aryl hydrocarbon receptor M Knockaert et al (Fernandez-Salguero et al., 1995; Schmidt et al., 1996; Lahvis et al., 2000) ; (4) disruption of AhR expression with antisense oligonucleotides or siRNA results in decreased mouse blastocyst development (Peters and Wiley, 1995) and abnormalities in cell cycle regulation (Ma and Whitlock, 1996; Weiss et al., 1996 , Abdelrahim et al, 2003 , for a review, see Elferink, 2003) .
Indoles (Miller, 1997; Heath-Pagliuso et al., 1998) , tetrapyroles, and arachidonic acid metabolites have been described as natural AhR ligands (reviewed in Denison and Nagy, 2003) . Many natural AhR ligands actually derive from dietary indoles (tryptophan, indole-3-carbinol) or flavonoids. Among indoles found in mammals are: (1) indirubin, purified from human urine and from fetal calf serum (Adachi et al., 2001) , (2) the recently described ITE (2-(1 0 H-indole-3 0 -carbonyl)-thiazole-4-carboxylic acid methyl ester), isolated from porcine lung (Song et al., 2002) and (3) the tryptophan photoproduct FICZ (6-formylindolo[3,2-b]carbazole) (Wei et al., 2000; Bergander et al., 2003) . However, none of these indoles is an unequivocal endogenous AhR ligand. For example, it cannot be excluded that ITE is a microbial contaminant. Similarly, indirubins present in mammals clearly derive from gut microflora. Nevertheless, indirubins may represent mimetics of endogenous indoles acting selectively on AhR for specific physiological functions. One hypothesis that deserves further exploration is that, under specific circumstances, cells produce endogenous AhR-regulating bis-indoles that are chemically related to indirubins. The demonstration of indirubin synthesis from indoles by human cytochrome P450 enzymes is particularly relevant in that respect (Gillam et al., 2000) . 
Biochemical and cellular effects of indirubins
Indirubins affect cell proliferation differently according to their concentration, to cell types, and to experimental conditions. Both a G1/S and a G2/M arrest have been observed (Hoessel et al., 1999; Damiens et al., 2001; Marko et al., 2001) . Therefore, IO (and BIO) have the capacity to arrest cells both in G1 and in G2/M, and what is observed depends on: (1) whether cells are presynchronized or not, and (2) the cell type, probably reflecting the specific proportion and distribution of each individual enzymatic target, which comprise protein kinases such as CDK1/cyclin B, CDK2/cyclin A-E, GSK-3, and other kinase targets (Leclerc et al., 2001; Bain et al., 2003) . Indirubins appear to bind in a manner similar to CDK2 (Hoessel et al., 1999; Davies et al., 2001 ), CDK5 and GSK-3 (Meijer et al., 2003; Polychronopoulos et al., 2004) and probably to other kinases as well, given the conserved structure of the ATP-binding pocket. Among the essential indirubin/ kinase bonds, the lactam amide nitrogen of indirubins (N1) donates a hydrogen bond to the backbone oxygen of Glu81 (CDK2), Glu81 (CDK5) or Asp 133 (GSK-3), three amino acids that occupy a homologous position in these kinases. Methylation of indirubins on N1 prohibits this interaction and inactivates the inhibitory properties of indirubins towards these and probably other kinases (Meijer et al., 2003; Polychronopoulos et al., 2004) . Compared to the nonmethylated indirubins, N1-methylated indirubins have little effect on cell survival as measured by the MTT assay, whether cells express AhR (5L) or not (BP8) (Figure 6 ). Importantly, these N1-methylated indirubins are potent AhR agonists. As such they affect cell proliferation by arresting cells in G1 in a strictly AhR-dependent manner ( Figure 5 ). These results suggest that indirubins such as IO and BIO reduce cell survival by a mechanism essentially independent from AhR (since similar rates of survival were observed in both 5L and BP8 cells), a mechanism likely to be a direct or indirect consequence of kinase inhibition. However, Indirubins, kinases and aryl hydrocarbon receptor M Knockaert et al both IO and BIO have a modest, but not insignificant effect on AhR as evidenced by the nuclear translocation of AhR they trigger and the limited (but clearly AhRdependent) p27 KIP1 induction and G1 arrest they induce. Nevertheless, this limited AhR agonist effect does not contribute to the antiproliferative effects of these indirubins based on the experimental conditions tested in this study.
The cellular response to a particular indirubin thus depends on its individual affinity for AhR and kinases and on its partition between the different targets in the cell. This depends essentially on three factors: (1) the intracellular distribution of the indirubin; (2) the intracellular distribution of the targets (the cell response will depend on the targets that interact first with the indirubin); (3) the expression and activity levels of each individual target. In this respect, we have observed large variations in the expression of AhR among different cell lines (data not shown). Similarly, the position of cells in the cell division cycle certainly plays a role in the activity of each CDK/cyclin complex.
In some case, the effect on AhR will predominate (cytostatic effect due to a G1 arrest) (Figure 8 ), while in other case, the effect on kinases will prevail (leading to a cytotoxic effect). Kinase-inactive indirubins will essentially act through AhR. Other indirubins seem to act more through kinase inhibition, although we have not identified so far an AhR-inactive indirubin with strong kinase inhibitory properties to demonstrate this possibility.
N1-methylated indirubins thus provide very interesting tools to challenge the functions of AhR in cell cycle regulation. These compounds are potent inducers of p27 KIP1 , and this provides an explanation for the observed G1 arrest. However, we cannot exclude the possibility that the cellular effects derive from the expression of other target genes. Differences in the mechanism of action of methylated and nonmethylated indirubins could be explained possibly by their differential metabolism. AhR agonists are indeed known to induce their own degradation, through the induction of cytochrome P450s. Although we have not investigated this point, it is possible that the N1-methylated indirubins are only short-lived, and the cellular response they induce only depends on the half-life of p27 KIP1 they have induced. In contrast, the nonmethylated indirubins may be much more stable in the cell environment, as they induce much less metabolizing cytochrome P450s. Being trapped in the ATP-binding pocket of various kinases, indirubins may have long-lasting effects on cells, resulting in irreversible effects and diminished cell viability.
The pharmacological use of indirubins
Given the diversity of targets, the use of indirubins as pharmacological tools to investigate cell function is limited and requires careful control experiments (such as cell lines in which the putative target has been knocked out). However, it is undoubtedly possible to develop indirubin sub-families with greatly enhanced selectivity for specific targets such as GSK-3 (6-bromo-indirubins) (Meijer et al., 2003; Polychronopoulos et al., 2004) or AhR (N1-methylated indirubins) (this article). Indirubins can then be evaluated for potential therapeutic applications according to their selectivity (GSK-3: type II diabetes; GSK-3 & CDK5: neurodegenerative disorders; CDKs: cancer; AhR: cancer) (Knockaert et al., 2002) . In the case of applications in the nervous system, AhR activation should be given careful attention, as AhR, ARNT and indigo-responsive XRE binding are widely distributed in the brain (Petersen et al., 2000; Kuramoto et al., 2003) .
There are several arguments that support the investigation of AhR ligands as antitumor agents (see reviews in Bradshaw et al., 2002; Safe and McDougal, 2002) . In particular, pancreatic tumor cell lines and human pancreatic cancer tissues express high levels of AhR and pancreatic cancer cell growth is inhibited by TCDD and other AhR ligands (Koliopanos et al., 2002) . Pancreatic tumors thus represent a promising therapeutic target for AhR-selective indirubins. Furthermore interference with the AhR signaling pathway contributes to leukemogenesis, as shown by an acute myeloblastic leukemia in which a fusion protein between translocated ETS leukemia (TEL) and ARNT is expressed (SalomonNguyen et al., 2000) , by the constitutive activation of AhR in adult T-cell leukemia (ATL) (Hayashibara et al., 2003) and by the benzene-induced AhR-dependent hematotoxicity/leukemogenesis (Yoon et al., 2002) . The AhR-binding properties of indirubins may thus Figure 8 Model for the dual mechanism of action of indirubins in dividing cells. Indirubins with a high affinity for AhR and low affinity for kinases bind to and activate AhR more readily. The AhR/indirubin complex translocates to the nucleus and forms a dimer with ARNT. This complex then binds to xenobioticresponsive elements (XRE) present in the regulatory domains of numerous target genes and directly or indirectly stimulates the expression of target genes, e.g. p27 KIP1 . p27 KIP1 is a potent inhibitor of CDK2, leading to a marked arrest in G1 and a subsequent cytostatic effect. Indirubins with a higher affinity for protein kinases inactivate CDKs, GSK-3, and probably other kinases. This induces cell cycle arrest at multiple stages, ultimately leading to reduced cell survival contribute to their long-reported effects on leukemia (see reviews in Tang and Eisenbrand, 1992; Xiao et al., 2002) .
Materials and methods
Chemistry
The synthesis of the nonmethylated indirubins used in this study have been published elsewhere (Polychronopoulos et al., 2004) . Compounds 3, 5, 6, 7, 8, 9, 19 and 20 were kindly provided by Dr G Eisenbrand (Department of Chemistry, Food, Chemistry and Environmental Toxicology, University of Kaiserslautern, Erwin-Schro¨dinger-Strasse, 67663 Kaiserslautern, Germany). Their synthesis was described previously (Leclerc et al., 2001 ).
1-Methyl-indirubin (3) Methanol (25 ml) was vigorously stirred under nitrogen for 20 min, then 1-methyl-isatin (128 mg, 0.8 mmol), 3-acetoxyindol (92 mg, 0.53 mmol) was added and stirring was continued for 5 min during which time the compounds dissolved. Anhydrous Na 2 CO 3 (213 mg, 2 mmol) was added and the stirring continued for 3 h. The dark precipitate was filtered, washed with aqueous methanol (1:1, 10 ml) and CH 2 Cl 2 (10 ml) to give 3 (65 mg, 0.24 mmol, 44%).
6-Bromo-1-methyl-indirubin (12) Methanol (20 ml) was vigorously stirred under nitrogen for 20 min, then 6-bromo-1-methyl-isatin (106 mg, 0.44 mmol), 3-acetoxyindol (61 mg, 0.35 mmol) was added and stirring was continued for 5 min during which time the compounds dissolved. Anhydrous Na 2 CO 3 (120 mg) was added and the stirring continued for 3 h. The dark precipitate was filtered, washed with aqueous methanol (1:1, 10 ml) and CH 2 Cl 2 (10 ml) to give 12 (60 mg, 0.17 mmol, 49% 
1-Methyl-indirubin-3 0 -oxime (4) (MeIO) 1-Methyl-indirubin (35 mg, 0.13 mmol) was dissolved in pyridine (3 ml). Then hydroxylamine hydrochloride (20 mg) was added and the mixture was heated under reflux (1201C) for 1.5 h. The solvent was evaporated under reduced pressure and the residue was washed with water and c-hexane to afford quantitatively MeIO (4) (37 mg 
1-Methyl-6-bromo-indirubin-3 0 -oxime (14) (MeBIO) 1-Methyl-6-bromo-indirubin (15 mg, 0.042 mmol) was dissolved in pyridine (2 ml). Then hydroxylamine hydrochloride (15 mg) was added and the mixture was heated under reflux (1201C) for 1.5 h. The solvent was evaporated under reduced pressure and the residue was washed with water and c-hexane to afford quantitatively MeBIO (14) Buffers Homogenization buffer: 60 mM b-glycerophosphate, 15 mM p-nitrophenylphosphate, 25 mM Mops (pH 7.2), 15 mM EGTA, 15 mM MgCl 2 , 1 mM DTT, 1 mM sodium vanadate, 1 mM NaF, 1 mM phenylphosphate, 10 mg leupeptin/ml, 10 mg aprotinin/ml, 10 mg soybean trypsin inhibitor/ml and 100 mM benzamidine.
Buffer A: 10 mM MgCl 2 , 1 mM EGTA, 1 mM DTT, 25 mM Tris-HCl pH 7.5, 50 mg heparin/ml.
Buffer C: homogenization buffer but 5 mM EGTA, no NaF and no protease inhibitors.
Kinase preparations and assays Kinase activities were assayed in Buffer A or C, at 301C, at a final ATP concentration of 15 mM. Blank values were subtracted and activities calculated as picomoles of phosphate incorporated for a 10-min incubation. The activities are usually expressed in % of the maximal activity, that is, in the absence of inhibitors. Controls were performed with appropriate dilutions of dimethylsulfoxide.
GSK-3 a/b was purified from porcine brain by affinity chromatography on immobilized axin (Primot et al., 2000) . It was assayed, following a 1/100 dilution in 1 mg BSA/ml 10 mM DTT, with 5 ml 40 mM GS-1 peptide as a substrate, in buffer A, in the presence of 15 mM [g-32 P]ATP (3000 Ci/mmol; 1 mCi/ml) in a final volume of 30 ml. After 30-min incubation at 301C, 25 ml aliquots of supernatant were spotted onto 2.5 Â 3 cm pieces of Whatman P81 phosphocellulose paper, and, 20 s later, the filters were washed five times (for at least 5 min each time) in a solution of 10 ml phosphoric acid/liter of water. The wet filters were counted in the presence of 1 ml ACS (Amersham) scintillation fluid. CDK1/cyclin B was extracted in homogenization buffer from M phase starfish (Marthasterias glacialis) oocytes and purified by affinity chromatography on p9 CKShs1 -sepharose beads, from which it was eluted by free p9
CKShs1 as previously described (Borgne and Meijer, 1996) . The kinase activity was assayed in buffer C, with 1 mg histone H1/ml, in the presence of 15 mM [g-32 P]ATP (3000 Ci/mmol; 1 mCi/ml) in a final volume of 30 ml. After 10-min incubation at 301C, 25 ml aliquots of supernatant were spotted onto P81 phosphocellulose papers and treated as described above.
CDK5/p25 was reconstituted by mixing equal amounts of recombinant mammalian CDK5 and p25 expressed in Escherichia coli as glutathione-S-transferase (GST) fusion proteins and purified by affinity chromatography on glutathione-agarose (vectors kindly provided by Dr JH Wang) (p25 is a truncated version of p35, the 35-kDa CDK5 activator). Its activity was assayed in buffer C as described for CDK1/cyclin B.
Cell biology
Chemical reagents 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) was a kind gift from Dr Steve Safe (Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, USA).
AhR assays
Yeast AhR reporter assay The Saccharomyces cerevisiae strain used for the yeast assay for AhR ligand activity was YCM3, derived from YPH499 (mat a, ade2-101, his3D200, leu2-1, lys2-801, trp-63, ura3-52) (Miller, 1997; Adachi et al., 2001) . It was kindly provided by Dr CA Miller III (Department of Environmental Health Sciences and Tulane-Xavier Center for Bioenvironmental Research, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA). Standard yeast growth conditions and genetic manipulations were previously described (Guthrie and Fink, 1991) . Yeast cells expressing both AhR and ARNT from the inducible GAL promoter were grown to early log phase at 251C in selective media containing raffinose (2% final concentration), at which time galactose (2%) was added for 3 h. Various concentrations of indirubins (in DMSO) were then added and the cells were grown for an additional 3 h and b-galactosidase activity was determined (adapted from Miller, 1999) . Briefly, 1 ml of cell culture was centrifuged and cells were washed and resuspended in 150 ml of Z-buffer (60 mM Na 2 HPO 4 , 40mM NaH 2 PO 4 , 1mM MgSO 4 , 10mM KCl, 40 mM b-mercaptoethanol). After addition of 50 ml chloroform and 10 ml of 0.1% SDS, the mix was vortexed for 15 s and the reaction was started by addition of 700 ml of o-nitrophenol-Dgalactopyranoside (1 mg/ml solution in Z-buffer) and further incubated for 10 min at 301C. The reaction was then stopped by addition of 500 ml of 1 M Na 2 CO 3 . b-Galactosidase (referred to as lacZ units) was measured at 420 nm and calculated according to the following formula: absorbance at 420 nm Â 1000/(absorbance at 600 nm Â ml of cell suspension added Â min of reaction time).
AhR-dependent EGFP expression assay in a stably transfected mouse hepatoma cell line Mouse hepatoma (H1G1.1c3) cells containing a stably transfected plasmid expressing XRE-driven EGFP fusion gene were maintained in selective media (aMEM containing 10% fetal bovine serum and 968 mg/l G418). XREs are high-affinity binding sites for AhR/ARNT transcription factor complex and they mediate ligand-and AhR-dependent transcriptional activation (Nagy et al., 2002a, b) . Cells were plated into black, clear-bottomed 96-well tissue culture dishes (Corning, San Mateo, CA, USA) at 75,000 cells per well and allowed to attach for 24 h. The selective medium was then replaced with 100 ml of media (lacking G418) containing the DMSO (1% final solvent concentration) or the test chemical at the indicated concentration. EGFP levels were measured in living cells at 24 h using a Tecan Genios microplate fluorometer with an excitation wavelength of 485 nm (25 nm bandwidth) and an emission wavelength of 515 nm (10 nm bandwidth). In order to normalize results between experiments, the instrument fluorescence gain setting was adjusted so that the level of EGFP induction by 1 nM TCDD produced a relative fluorescence of 9000 relative fluorescence units (RFUs). Samples were run in triplicate and the fluorescent activity present in wells containing media only was subtracted from the fluorescent activity in all samples.
Cell proliferation analysis
The mouse 5L hepatoma cell line (AhR þ / þ ) and BP8 (an AhR À/À subclone) were kindly provided by Dr M Gottlicher (Forschungszentrum Karlsruhe, Institute of Genetics, Karlsruhe, Germany). Cells were cultured in Dulbecco's modified Eagle medium (DMEM) (Biowhittaker) supplemented with 2 mM L-glutamine (Eurobio), 10% fetal calf serum (FCS), and gentamycin (Gibco BRL) at 371C in an atmosphere of 7% CO 2 . Indirubin treatments were performed on 50-60% confluent cultures at the indicated time and concentrations (Damiens et al., 2001) . Control experiments were carried out using appropriate dilutions of DMSO.
Cell viability assay
To quantify the toxicity of indirubins on 5L and BP8 cells, we measured the inhibition of cellular reduction of MTT to MTT formazan according to Mosmann (1983) . After treatment with indirubins, cells were incubated with 0.5 mg MTT/ml fresh medium at 371C for 1 h. The formazan products were dissolved in DMSO and quantified by measurement of the absorbance at 562 nm.
FACS analysis
Flow cytometry analysis (Coulter EPIX XL2, Beckman, CA, USA) of cellular DNA content was performed on ethanolfixed cell suspensions after ribonuclease A III treatment (Sigma) and propidium iodide (Sigma) staining, as previously described (Ffrench et al., 1985) . Percentages of cells in G0/G1, S and G2/M phases of cell cycle were then calculated on the basis of DNA distribution histograms provided by the software manufacturer.
Indirect immunofluorescence microscopy
The wild-type mouse hepatoma cells (Hepa-1) and its variant ARNT mutant cells (lacking functional ARNT) were grown in minimum essential medium (InVitrogen, Carlsbad, CA, USA) supplemented with 6% FBS (Hyclone Laboratories, Logan, UT, USA). Cells were routinely maintained in a 371C incubator with 5% CO 2 . Cells were treated for 90 min with control vehicle, DMSO or with ligands, TCDD at 10 nM and indirubins at 25 mM. The cells were fixed in 2% paraformaldehyde and processed for indirect immunofluorescence microscopy as previously described (Elbi et al., 2002) . Polyclonal anti-AhR primary antibody was used at 1 : 400 (Biomol Research Laboratories, Plymouth, PA, USA). The cells were mounted using Prolong (Molecular Probes, Eugene, OR, USA) and were observed on a Nikon E800 microscope equipped with 63 Â 1.35 NA, oil immersion Plano Nikon objective and a Photometrics MicroMax cooled CCD camera. Images were collected by using the MetaMorph software (Universal Imaging, Downingtown, PA, USA).
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